Schrödinger (SDGR) closed near $29.45 after a powerful rally that took shares roughly 140% higher over six months and pushed the stock to fresh 52-week highs. The $40 stock price target represents a meaningful move of roughly 35% above recent levels and sits well above the stock's current 52-week high near $31.59.

The widely discussed price objective for Target Hospitality Corp. (TH) is $25, roughly in line with the Street's consensus analyst price target of about $25.20. The strongest bullish driver is a wave of multi-year data center and "hyperscaler" workforce-housing contracts, including more than $1.7 billion in awards secured since January 2026.

Freenome, Inc. ( FRNM ) is a development-stage biotech focused on blood-based early cancer detection, and the question is whether its stock can reach a $20 price target from roughly $16. Reaching $20 would require the stock to climb about 25% and decisively clear its 52-week high of $17.50.

ASST climbed roughly 37% over the trailing 30 days, rising from about $21.50 to near $29.50, as Strive accelerated its Bitcoin treasury accumulation. Strive added approximately 3,200 BTC across three disclosed purchases during the period, lifting its holdings to 26,355 BTC and a top-five ranking among public corporate Bitcoin holders.

Alvotech (ALVO) shares have climbed roughly 20% over the last 30 days, moving from about $4.91 to around $5.89. The advance was driven by a rare Barclays double upgrade, Bank of America's Buy initiation, and FDA acceptance of the company's AVT80 biosimilar application.

Inspire Medical Systems (INSP) shares climbed roughly 11% over the trailing 30 days, moving from about $61.80 to near $68.66. The advance extends a broader recovery, with the stock up more than 50% over the trailing three months after a difficult first half of the year.

Okeanis Eco Tankers (ECO) shares rose roughly 20.3% over the last 30 days, from a close of $65.04 on August 25, 2026 to $78.22 on September 24, 2026. The move extended a broader rally: the stock advanced about 43.7% over the last three months, supported by surging crude tanker spot rates and geopolitical shipping disruptions.

AtriCure (ATRC) shares climbed roughly 26% over the last 30 days, rising from about $48.17 to a closing level near $60.77. The rally has been part of a broader multi-month advance, with the stock trading at or near 52-week highs through mid-to-late September 2026.

GeneDx Holdings (WGS) shares finished the past 30 days roughly flat near $88, after rallying above $100 in mid-September before pulling back on elevated volume. The company is a leader in whole exome and genome sequencing for pediatric and rare disease diagnosis, powered by its GeneDx Infinity genomic dataset.

The selected price target is $8 , the Street-high target held by B. Riley Securities and roughly 44% above the recent closing price. The strongest bullish factors are six consecutive quarters of double-digit revenue growth, raised guidance, and a new long-term operating margin target.

The selected price target is $20 per share , a round psychological level that sits roughly 42% above PURR's latest closing price near $14. Wall Street consensus is constructive: analysts broadly rate the stock a Buy or Strong Buy, with average 12-month price targets clustered around the high teens to low $20s.

The central question is whether Ionic Digital Inc. (NASDAQ: IOND) can reach a $100 stock price target, a psychological milestone roughly 18% above its recent closing level near $85. Bullish factors include rapid revenue growth, a debt-light balance sheet with substantial cash, and exposure to two high-demand themes: AI-driven high-performance computing (HPC) and bitcoin mining.

Delek US Holdings shares traded near $66.91 at the latest close, down roughly 5.5% from about $70.84 thirty days earlier — a modest pullback after a prolonged run higher. The recent decline was driven largely by the company's proposed and then priced $400 million convertible senior notes offering, which raised potential equity-dilution concerns.

Target level: The widely discussed $100 stock price target sits roughly 38% above recent prices and matches the highest published analyst objective. Bullish case: Accelerating digital revenue, a rapidly improving balance sheet, and a formal buyback program support higher valuations.

Dyne Therapeutics (DYN) shares fell roughly 37% over the last 30 days, declining from about $26.34 to $16.51. The sharp selloff was triggered by Novartis (NVS) reporting a Phase 3 failure for del-desiran in myotonic dystrophy type 1 (DM1), rattling the broader muscle-disease drug sector.

The central question is whether Signet Jewelers Limited (SIG) can reach the $150 price level, roughly 49% above its recent price near $100.50. The bullish case rests on a margin turnaround, self-help profit drivers, and new leadership, with Jefferies and Stephens carrying $150–$175 price targets.

Axcelis Technologies (ACLS) traded near $116 per share in late September 2026, roughly 3.5% below its level of a month earlier. Second-quarter 2026 revenue rose 10.6% year over year to $215.2 million, prompting management to raise its full-year outlook to mid-single-digit growth.

FRMI closed down -5.60% (-$0.27) at $4.55 during the regular session, versus the prior close of $4.82. The decline came without a company-specific negative catalyst, driven by continued selling pressure in AI infrastructure names amid a broader risk-off tone.

Figma (FIG) shares declined roughly 21% over the past 30 days, falling from a close near $27.03 on August 26, 2026, to about $21.34 by September 24, 2026. The pullback followed a sharp late-August spike, with the stock briefly trading near $30.62 before a multi-week slide erased those gains.

Bending Spoons shares have declined roughly 23% over the past 30 days, pulling back from about $42 to near $33. The retreat follows a sharp post-listing rally that carried the stock from its $29 IPO price to an intraday high near $59 in early August.